-
Mashup Score: 2
– Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children’s Research Hospital, Inc. and two other clinical sites – – New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD – TEL AVIV, Israel, May 30, 2024 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today
Source: stocks.apple.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Larry Ellison’s vision for the future of medicine crystallized for him in a doctor’s office. Oracle’s billionaire cofounder needed medication to help manage his cholesterol. He said his “very fancy doctor,” a molecular biologist, prescribed a statin called Crestor. The choice was informed by Ellison’s age, sex, ethnicity, and family history. But it was still, Ellison realized, just “a pretty good guess.” Which got him thinking: What if, instead of guesswork, doctors could lean on generative AI
Source: stocks.apple.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Steward Health Care files for Chapter 11 bankruptcy - 26 day(s) ago
Steward Health Care, the struggling hospital group that owns hospitals in Massachusetts, Texas, Florida and other states, announced Monday that it is filing for bankruptcy.
Source: stocks.apple.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain - 1 month(s) ago
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting enrollment to begin in the second quarter of 2024 BROOMFIELD, CO, April 25, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence
Source: stocks.apple.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1Sneakerheads losing interest and spending less - 1 month(s) ago
Sneak-er-head/snēker hed/: a sneaker enthusiast.
Source: stocks.apple.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, fixed-site outpatient diagnostic imaging services through a network of 366 owned and/or operated outpatient imaging centers, announced today that it established a new joint
Source: stocks.apple.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1Warren Buffett-backed EV maker BYD surprises with stellar first quarter sales as Tesla continues to slide - 2 month(s) ago
BYD surpassed Tesla in quarterly sales for the first time late last year.
Source: stocks.apple.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Nvidia's AI ambitions in medicine and health care are becoming clear - 2 month(s) ago
Applying Nvidia AI chips to health care, whether it’s biotechnology, chemicals, or drug discovery is going to be a big business.
Source: stocks.apple.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Regeneron, Vertex Pharma join $100B club in biotech - 3 month(s) ago
Regeneron (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) have crossed $100B in market capitalization for the first time, joining two other giants in the biotech industry, Amgen (AMGN) and AbbVie (ABBV). New York-based Regeneron (REGN) and Vertex Pharmaceuticals (VRTX), headquartered in Massachusetts, have both outperformed their rivals over the past twelve months, rising ~27% and ~44%, respectively, compared to a mere ~3% gain in the Nasdaq Biotechnology Index (NBI). According to market
Source: stocks.apple.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0RadNet and JVS SoCal Create ImagingWorks®, an Innovative Partnership to Launch Career Training Programs for Medical Imaging - 4 month(s) ago
RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces the formation of a new diagnostic imaging career training program created in partnership with JVS
Source: stocks.apple.comCategories: General Medicine News, Expert PicksTweet
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) - #ASCO24 https://t.co/YsUZMZx9zG